Modulation of monoamine receptors by adaptor proteins and lipid rafts: Role in some effects of centrally acting drugs and therapeutic agents

Annual Review of Pharmacology and Toxicology

Volumn 51, Issue , 2011, Pages 211-242

  Bj̈ork, Karl ^a   Svenningsson, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

caveolin; dopamine; GPCR; ligand bias; scaffolding proteins; serotonin

Indexed keywords

ADAPTOR PROTEIN; ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; CALCIUM; CALNEXIN; CAVEOLIN; CHOLESTEROL; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; FLUOXETINE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MONOAMINE; MONOAMINE DRIP78; NEUROLEPTIC AGENT; PEPTIDE; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN NCS 1; PROTEIN S100B; RETINA S ANTIGEN; SEROTONIN 1B RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN RECEPTOR; SPINOPHILIN; UNCLASSIFIED DRUG;

ARTICLE; BIPOLAR DEPRESSION; CELL MEMBRANE; DENDRITIC CELL; DRUG ABUSE; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG THERAPY; ENDOPLASMIC RETICULUM; HUMAN; LIPID RAFT; LYSOSOME; MAJOR DEPRESSION; NERVE CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BIOGENIC MONOAMINES; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MEMBRANE MICRODOMAINS; RECEPTORS, BIOGENIC AMINE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 79951964192     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010510-100520     Document Type: Article

References (201)

1. Greengard P. 2001. The neurobiology of slow synaptic transmission. Science 294:1024-30 (Pubitemid 33041850)
2. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: from structure to function. Physiol. Rev. 78:189-225 (Pubitemid 28070979)
3. Bouvier M. 2001. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2:274-86 (Pubitemid 33673068)
4. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, et al. 2007. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol. Rev. 59:5-13 (Pubitemid 46335687)
5. Bridges TM, Lindsley CW. 2008. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem. Biol. 3:530-41
6. Lefkowitz RJ, Shenoy SK. 2005. Transduction of receptor signals by β-arrestins. Science 308:512-17
7. Pierce KL, Lefkowitz RJ. 2001. Classical and new roles of β-arrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2:727-33 (Pubitemid 33674818)
8. 2A serotonin receptors by scaffolding proteins and kinases. Neuropharmacology 55:961-68
9. Bockaert J, Perroy J, Bécamel C, Marin P, Fagni L. 2010. GPCR interacting proteins (GIPs) in the nervous system: roles in physiology and pathologies. Annu. Rev. Pharmacol. Toxicol. 50:89-109
10. Millan MJ, Marin P, Bockaert J, la Cour CM. 2008. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol. Sci. 29:454-64
11. 2+ connection in dopamine signaling. Trends Pharmacol. Sci. 24:486-92 (Pubitemid 37088174)
12. Björk K, Sjögren B, Svenningsson P. 2010. Regulation of serotonin receptor function in the nervous system by lipid rafts and adaptor proteins. Exp. Cell Res. 316:1351-56
13. Ritter SL, Hall RA. 2009. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 10:819-30
14. Ferguson SSG, Downey WE III, Colapietro AM, Barak LS, Menard L, Caron MG. 1996. Role of β-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271:363-66
15. Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, et al. 1992. β-arrestin2, a novel member of the arrestin/β-arrestin gene family. J. Biol. Chem. 267:17882-90
16. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. 1990. β-Arrestin: a protein that regulates β-adrenergic receptor function. Science 248:1547-50
17. 2-adrenergic receptor. Nature 383:447-50 (Pubitemid 26330835)
18. 2A receptors during endocytosis. J. Biol. Chem. 276:8269-77
19. 2A receptor induces agonist-independent internalization. Mol. Pharmacol. 63:961-72 (Pubitemid 36529914)
20. 4a receptor regulates receptor phosphorylation, desensitization, and β-arrestin-mediated endocytosis. Mol. Pharmacol. 67:1434-43 (Pubitemid 40594142)
21. Svenningsson P, Greengard P. 2007. p11 (S100A10)-an inducible adaptor protein that modulates neu-ronal functions. Curr. Opin. Pharmacol. 7:27-32
22. 1B receptor function by p11 in depression-like states. Science 311:77-80 (Pubitemid 43063061)
23. Warner-Schmidt JL, Flajolet M, Maller A, Chen EY, Qi H, et al. 2009. Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J. Neurosci. 29:1937-46
24. 2C receptors: a proteomic approach. EMBO J. 21:2332-42 (Pubitemid 34546706)
25. 2A serotonin receptors regulates receptor trafficking and signal transduction. J. Biol. Chem. 278:21901-8 (Pubitemid 36792597)
26. 2C receptors interact with specific sets of PDZ proteins. J. Biol. Chem. 279:20257-66 (Pubitemid 38623471)
27. 1-adrenergic receptor interaction with N-methyl-D-aspartate receptors. J. Biol. Chem. 275:38659-66 (Pubitemid 32009197)
28. 2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience 122:907-20 (Pubitemid 37485844)
29. Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SGN, et al. 2009. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J. Neurosci. 29:7124-36
30. 2C receptor desensitization and membrane stability. Mol. Biol. Cell 17:4619-31 (Pubitemid 44665733)
31. 1A serotonin receptor to neuronal dendrites is mediated by Yif1B. J. Neurosci. 28:8063-73
32. + exchange. Nature 392:626-30 (Pubitemid 28207723)
33. 2-adrenergic receptor. Nature 401:286-90
34. Heydorn A, Sondergaard BP, Hadrup N, Holst B, Haft CR, Schwartz TW. 2004. Distinct in vitro interaction pattern of dopamine receptor subtypes with adaptor proteins involved in post-endocytotic receptor targeting. FEBS Lett. 556:276-80 (Pubitemid 38058592)
35. 2 adrenergic receptor to N-ethylmaleimide-sensitive factor regulates receptor recycling. J. Biol. Chem. 276:45145-52
36. Wang Y, Zhou Y, Szabo K, Haft CR, Trejo J. 2002. Down-regulation of protease-activated receptor-1 is regulated by sorting nexin 1. Mol. Biol. Cell 13:1965-76 (Pubitemid 34651486)
37. 4 splice variant. J. Neurochem. 74:478-89 (Pubitemid 30053719)
38. 4 receptor variants. Neuropharmacology 42:60-73 (Pubitemid 34062822)
39. 4(a) receptor splice variant: roles in receptor targeting. J. Cell Sci. 117:5367-79 (Pubitemid 39562498)
40. 1 receptor by a new membrane-associated ER protein. Nat. Cell Biol. 3:492-98 (Pubitemid 32422085)
41. 2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin. J. Biol. Chem. 282:21285-300 (Pubitemid 47099963)
42. 4 receptors define a novel mode of regulation of G protein-coupled receptors. Mol. Biol. Cell 15:696-705 (Pubitemid 38146486)
43. 2 receptor signaling. Mol. Biol. Cell 15:4926-37 (Pubitemid 39392208)
44. Abramow-Newerly M, Roy AA, Nunn C, Chidiac P. 2006. RGS proteins have a signaling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. Cell. Signal. 18:579-91 (Pubitemid 43113289)
45. Allen PB, Ouimet CC, Greengard P. 1997. Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines. Proc. Natl. Acad. Sci. USA 94:9956-61 (Pubitemid 27408172)
46. Satoh A, Nakanishi H, Obaishi H, Wada M, Takahashi K, et al. 1998. Neurabin-II/spinophilin: an actin filament-binding protein with one PDZ domain localized at cadherin-based cell-cell adhesion sites. J. Biol. Chem. 273:3470-75 (Pubitemid 28109767)
47. Feng J, Yan Z, Ferreira A, Tomizawa K, Liauw JA, et al. 2000. Spinophilin regulates the formation and function of dendritic spines. Proc. Natl. Acad. Sci. USA 97:9287-92 (Pubitemid 30626711)
48. Ryan XP, Alldritt J, Svenningsson P, Allen PB, Wu GY, et al. 2005. The Rho-specific GEF Lfc interacts with neurabin and spinophilin to regulate dendritic spine morphology. Neuron 47:85-100 (Pubitemid 40922852)
49. 2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein. J. Biol. Chem. 274:19894-900
50. 2+ signaling by binding the N-terminal domain ofRGS2 and the third intracellular loop of G-protein-coupled receptors. Nat. Cell Biol. 7:405-11 (Pubitemid 40533131)
51. Allen PB, Zachariou V, Svenningsson P, Lepore AC, Centonze D, et al. 2006. Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity. Neuroscience 140:897-911 (Pubitemid 43767470)
52. 2B- adrenergic receptors. J. Biol. Chem. 278:32405-12 (Pubitemid 37048438)
53. Wang Q, Zhao J, Brady AE, Feng J, Allen PB, et al. 2004. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 304:1940-44 (Pubitemid 38822181)
54. +-ATPase. Mol. Biol. Cell 18:4508-18 (Pubitemid 350060177)
55. 2 dopamine receptor. J. Neurosci. 22:8476-86 (Pubitemid 35387588)
56. Saab BJ, Georgiou J,Nath A,Lee FJS, Wang M,et al. 2009. NCS-1 inthe dentate gyrus promotes exploration, synaptic plasticity, and rapid acquisition of spatial memory. Neuron 63:643-56
57. 2 receptor function. Mol. Pharmacol. 74:371-78
58. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, et al. 2009. S100B's double life: intracellular regulator and extracellular signal. Biochim. Biophys. Acta 1793:1008-22
59. Ellis EF, Willoughby KA, Sparks SA, Chen T. 2007. S100B protein is released from rat neonatal neurons, astrocytes, and microglia by in vitro trauma and anti-S100 increases trauma-induced delayed neuronal injury and negates the protective effect of exogenous S100B on neurons. J. Neurochem. 101:1463-70 (Pubitemid 46848857)
60. Reeves RH, Yao J, Crowley MR, Buck S, Zhang X, et al. 1994. Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. Proc. Natl. Acad. Sci. USA 91:5359-63 (Pubitemid 24174326)
61. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. 2000. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J. Biol. Chem. 275:40096-105 (Pubitemid 32064635)
62. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. 2005. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-73 (Pubitemid 41032989)
63. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ. 2004. Differential kinetic and spatial patterns of β-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J. Biol. Chem. 279:35518-25 (Pubitemid 39100552)
64. 2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling. Mol. Biol. Cell 19:4640-50
65. 4 receptor signaling. EMBO J. 28:2706-18
66. Violin JD, Lefkowitz RJ. 2007. β-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28:416-22
67. Wei H, Ahn S, Barnes WG, Lefkowitz RJ. 2004. Stable interaction between β-arrestin 2 and angiotensin type 1A receptor is required for β-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2. J. Biol. Chem. 279:48255-61 (Pubitemid 39540982)
68. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, et al. 2006. β-arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J. Biol. Chem. 281:1261-73
69. 2 adrenergic receptor-Src protein kinase complexes. Science 283:655-61
70. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, et al. 2001. Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc. Natl. Acad. Sci. USA 98:2449-54 (Pubitemid 32209502)
71. 2- adrenergic G protein-coupled receptor. Science 318:1258-65 (Pubitemid 350172884)
72. 2-adrenergic receptor. Structure 16:897-905 (Pubitemid 351778384)
73. 1A receptor. Cell. Mol. Neurobiol. 27:1097-116 (Pubitemid 351170067)
74. Singer SJ, Nicolson GL. 1972. The fluid mosaic model of the structure of cell membranes. Science 175:720-31
75. Lingwood D, Simons K. 2010. Lipid rafts as a membrane-organizing principle. Science 327:46-50
76. Fantini J, Barrantes FJ. 2009. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim. Biophys. Acta 1788:2345-61
77. Patel HH, Murray F, Insel PA. 2008. Caveolae as organizers of pharmacologically relevant signal trans-duction molecules. Annu. Rev. Pharmacol. Toxicol. 48:359-91 (Pubitemid 351738158)
78. s/adenylyl cyclase signaling. Mol. Pharmacol. 76:1082-93
79. Ostrom RS. 2002. New determinants of receptor-effector coupling: trafficking and compartmentation in membrane microdomains. Mol. Pharmacol. 61:473-76 (Pubitemid 34171912)
80. Nabi IR. 2009. Cavin fever: regulating caveolae. Nat. Cell Biol. 11:789-91
81. Liu P, Rudick M, Anderson RGW. 2002. Multiple functions of caveolin-1. J. Biol. Chem. 277:41295-98 (Pubitemid 35257426)
82. Gaudreault SB, Blain JF, Gratton JP, Poirier J.2005.A role for caveolin-1inpost-injury reactive neuronal plasticity. J. Neurochem. 92:831-39 (Pubitemid 40229555)
83. Head BP, Insel PA. 2007. Do caveolins regulate cells by actions outside of caveolae? Trends Cell Biol. 17:51-57 (Pubitemid 46199179)
84. Gioiosa L, Raggi C, Ricceri L, Jasmin JF, Frank PG, et al. 2008. Altered emotionality, spatial memory and cholinergic function in caveolin-1 knock-out mice. Behav. Brain Res. 188:255-62
85. Trushina E, Du Charme J, Parisi J, McMurray CT. 2006. Neurological abnormalities in caveolin-1 knock out mice. Behav. Brain Res. 172:24-32 (Pubitemid 44037815)
86. q-coupled protein receptors. J. Biol. Chem. 279:34614-23 (Pubitemid 39318091)
87. 1 dopamine receptor signaling involves caveolin-2 in HEK-293 cells. Kidney Int. 66:2167-80 (Pubitemid 41115280)
88. Kong MMC, Hasbi A, Mattocks M, Fan T, O'Dowd BF, George SR. 2007. Regulation of D1 dopamine receptor trafficking and signaling by caveolin-1. Mol. Pharmacol. 72:1157-70 (Pubitemid 350012590)
89. Schwencke C, Okumura S, Yamamoto M, Geng YJ, Ishikawa Y. 1999. Colocalization of β-adrenergic receptors and caveolin within the plasma membrane. J. Cell. Biochem. 75:64-72 (Pubitemid 29402545)
90. 2-adrenoceptors in neonatal cardiac myocytes. J. Biol. Chem. 277:34280-86
91. 2-adrenergic regulation. Proc. Natl. Acad. Sci. USA 103:7500-5 (Pubitemid 43727862)
92. 2 receptor heterodimers. J. Mol. Neurosci. 26:177-84 (Pubitemid 41389410)
93. 2-adrenoceptor subtypes: dependence on receptor subtype and employed agonist. Eur. J. Cell Biol. 82:231-39 (Pubitemid 36656569)
94. 7(a) receptors. FEBS Lett. 581:5115-21 (Pubitemid 47576096)
95. 1A receptor in lipid microdomains depends on its palmitoylation and is involved in receptor-mediated signaling. Mol. Pharmacol. 72:502-13 (Pubitemid 47347285)
96. 7(a) receptors. Eur. J. Pharmacol. 552:1-10 (Pubitemid 44648071)
97. 7(a) receptors in HeLa cells. Acta Physiol. 190:47-53 (Pubitemid 46570170)
98. 1A receptor-mediated signaling in human primary neuronal cultures. Naunyn-Schmiedeberg's Arch. Pharmacol. 378:441-46
99. 1A receptors. Biochim. Biophys. Acta 1778:2022-25
100. Metherell LA, Chapple JP, Cooray S, David A, Becker C, et al. 2005. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat. Genet. 37:166-70
101. Porter FD. 2008. Smith -Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur. J. Hum. Genet. 16:535-41 (Pubitemid 351594119)
102. Chang TY, Reid PC, Sugii S, Ohgami N, Cruz JC, Chang CCY. 2005. Niemann-Pick type C disease and intracellular cholesterol trafficking. J. Biol. Chem. 280:20917-20 (Pubitemid 40805646)
103. Boomkamp SD, Butters TD. 2008. Glycosphingolipid disorders of the brain. Subcell. Biochem. 49:441-67
104. Menge T, Hartung HP, Stuve O. 2005. Statins-a cure-all for the brain? Nat. Rev. Neurosci. 6:325-31
105. 2C receptors suppresses behavioral responses induced by drugs of abuse. Nat. Med. 12:324-29 (Pubitemid 43355081)
106. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, et al. 2002. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 298:846-50 (Pubitemid 35231541)
107. Wells JA, McClendon CL. 2007. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450:1001-9 (Pubitemid 350273630)
108. Kenakin T. 2002. Efficacy at G-protein-coupled receptors. Nat. Rev. Drug Discov. 1:103-10 (Pubitemid 41646517)
109. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, et al. 2007. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320:1-13 (Pubitemid 46025713)
110. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, et al. 2008. Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc. Natl. Acad. Sci. USA 105:13656-61
111. Wise RA. 2008. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox. Res. 14:169-83
112. Robinson TE, Berridge KC. 2003. Addiction. Annu. Rev. Psychol. 54:25-53 (Pubitemid 37417487)
113. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 85:5274-78
114. Koob GF, Le Moal M. 2001. Drug addiction, dysregulation of reward, and allostasis. Neuropsychophar-macology 24:97-129
115. Kalivas PW, Volkow ND. 2005. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry 162:1403-13 (Pubitemid 41105554)
116. Heilig M, Koob GF. 2007. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 30:399-406 (Pubitemid 47090230)
117. Spanagel R, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, et al. 2005. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat. Med. 11:35-42 (Pubitemid 40215835)
118. Kreek MJ, Zhou Y, Butelman ER, Levran O. 2009. Opiate and cocaine addiction: from bench to clinic and back to the bench. Curr. Opin. Pharmacol. 9:74-80
119. Kindlundh-Högberg AM, Zhang X, Svenningsson P. 2009. S100B overexpressing mutant mice exhibit prolonged behavioural and biochemical responses towards repeated intermittent binge treatments with MDMA. Int. J. Neuropsychopharmacol. 12:201-15
120. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. 1999. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286:2495-98
121. Spanagel R, Herz A, Shippenberg TS. 1992. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. USA 89:2046-50
122. Bohn LM, Gainetdinov RR, Sotnikova TD, Medvedev IO, Lefkowitz RJ, et al. 2003. Enhanced rewarding properties of morphine, but not cocaine, in βarrestin-2 knock-out mice. J. Neurosci. 23:10265-73 (Pubitemid 37444603)
123. Björk K, Rimondini R, Hansson AC, Terasmaa A, Hyytiä P, et al. 2008. Modulation of voluntary ethanol consumption by beta-arrestin 2. FASEB J. 22:2552-60 (Pubitemid 351948672)
124. Yao WD, Gainetdinov RR, Arbuckle MI, Sotnikova TD, Cyr M, et al. 2004. Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron 41:625-38 (Pubitemid 38253073)
125. Schmid CL, Raehal KM, Bohn LM. 2008. Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo. Proc. Natl. Acad. Sci. USA 105:1079-84 (Pubitemid 351282084)
126. 2A receptor-mediated signaling pathways to affect behavior. Neuron 53:439-52 (Pubitemid 46161267)
127. 2C receptors. Eur. J. Pharmacol. 480:151-62 (Pubitemid 37410367)
128. Heilig M, Thorsell A, Sommer WH, Hansson AC, Ramchandani VA, et al. 2010. Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci. Biobehav. Rev. 35:334-44
129. Heilig M, Egli M. 2006. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol. Ther. 111:855-76 (Pubitemid 44118437)
130. Bai J, He F, Novikova SI, Undie AS, Dracheva S, et al. 2004. Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Biol. Psychiatry 56:427-40 (Pubitemid 39195323)
131. Koh PO, Bergson C, Undie AS, Goldman-Rakic PS, Lidow MS. 2003. Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Arch. Gen. Psychiatry 60:311-19 (Pubitemid 36307443)
132. Clinton SM, Ibrahim HM, Frey KA, Davis KL, Haroutunian V, Meador-Woodruff JH. 2005. Dopamin-ergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. Am. J. Psychiatry 162:1859-71 (Pubitemid 41428615)
133. Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, et al. 2001. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol. Psychiatry 6:445-49 (Pubitemid 32566096)
134. Steiner J, Walter M, Guest P, Myint AM, Schiltz K, et al. 2010. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol. Psychiatry 15:3-4
135. Steiner J, Walter M, Wunderlich MT, Bernstein HG, Panteli B, et al. 2009. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol. Psychiatry 65:1107-10
136. 3 receptors in raft-like domains. J. Neurosci. 25:10198-206 (Pubitemid 41636216)
137. Sanchez-Wandelmer J, Hernandez-Pinto AM, Cano S, Davalos A, de la Pena G, et al. 2009. Effects of the antipsychotic drug haloperidol on the somastostatinergic system in SH-SY5Y neuroblastoma cells. J. Neurochem. 110:631-40
138. Sanchez-Wandelmer J, Davalos A, de la Pena G, Cano S, Giera M, et al. 2010. Haloperidol disrupts lipid rafts and impairs insulin signaling in SH-SY5Y cells. Neuroscience 167:143-53
139. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, et al. 2007. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13:1102-7 (Pubitemid 47517511)
140. Karlsson RM, Tanaka K, Heilig M, Holmes A. 2008. Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psy-chotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist. Biol. Psychiatry 64:810-14
141. Moghaddam B. 2004. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 174:39-44 (Pubitemid 38925089)
142. Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P. 2010. Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice. Biol. Psychiatry 67:1048-56
143. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, et al. 2009. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62:479-93
144. Klein PS, Melton DA. 1996. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA 93:8455-59 (Pubitemid 26269579)
145. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, et al. 2008. A β-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125-36
146. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60:441-60
147. Park SK, Nguyen MD, Fischer A, Luke MP, Affar el B, et al. 2005. Par-4 links dopamine signaling and depression. Cell 122:275-87 (Pubitemid 41032990)
148. Murphy DL, Fox MA, Timpano KR, Moya PR, Ren-Patterson R, et al. 2008. How
149. Magnani F, Tate CG, Wynne S, Williams C, Haase J. 2004. Partitioning of the serotonin transporter into lipid microdomains modulates transport of serotonin. J. Biol. Chem. 279:38770-78 (Pubitemid 39296035)
150. Donati RJ, Dwivedi Y, Roberts RC, Conley RR, Pandey GN, Rasenick MM. 2008. Postmortem brain tissue of depressed suicides reveals increased Gsαlocalization in lipid raft domains where it is less likely to activate adenylyl cyclase. J. Neurosci. 28:3042-50 (Pubitemid 351442293)
151. s from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound. J. Pharmacol. Exp. Ther. 332:977-84
152. Donati RJ, Rasenick MM. 2005. Chronic antidepressant treatment prevents accumulation of Gsα in cholesterol-rich, cytoskeletal-associated, plasma membrane domains (lipid rafts). Neuropsychopharmacol-ogy 30:1238-45 (Pubitemid 40848078)
153. Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Berner P, et al. 1992. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26:59-64
154. 1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. USA 105:2163-68 (Pubitemid 351439482)
155. 1A-adrenoceptor- operated calcium influx through TRPC6. J. Biol. Chem. 282:29563-73 (Pubitemid 350043391)
156. Stanasila L, Abuin L, Diviani D, Cotecchia S. 2006. Ezrin directly interacts with the α1b-adrenergic receptor and plays a role in receptor recycling. J. Biol. Chem. 281:4354-63 (Pubitemid 43847867)
157. 1b-adrenergic receptor and plays a role in receptor endocytosis. J. Biol. Chem. 278:19331-40 (Pubitemid 36799327)
158. Wang X, Zeng W, Kim MS, Allen PB, GreengardP, MuallemS. 2007. Spinophilin/neurabin reciprocally regulate signaling intensity by G protein-coupled receptors. EMBO J. 26:2768-76 (Pubitemid 46884271)
159. 1D-adrenergic receptors through a PDZ domain-mediated interaction. J. Biol. Chem. 281:12414-20 (Pubitemid 43855326)
160. 2-adrenergic receptors inhibits agonist-mediated p44/42 MAP kinase activation. Cell. Signal. 21:1513-21
161. 1-adrenergic receptor promotes recycling and functional resensitization of the receptor. J. Biol. Chem. 281:33537-53 (Pubitemid 46036735)
162. 1-adrenergic receptor-mediated ERK activation. J. Biol. Chem. 278:26295-301 (Pubitemid 36835399)
163. 1-adrenergic receptor. Proc. Natl. Acad. Sci. USA 96:12559-64 (Pubitemid 29513541)
164. 1-adrenergic receptor association with the synaptic scaffolding protein membrane-associated guanylate kinase inverted-2 (MAGI-2): differential regulation of receptor internalization by MAGI-2 and PSD-95. J. Biol. Chem. 276:41310-17
165. Pak Y, Pham N, Rotin D. 2002. Direct binding of the β1 adrenergic receptor to the cyclic AMP-dependent guanine nucleotide exchange factor CNrasGEF leads to Ras activation. Mol. Cell. Biol. 22:7942-52 (Pubitemid 35217303)
166. 1-adrenergic receptor interactions with PDZ scaffold proteins. J. Biol. Chem. 281:2820-27 (Pubitemid 43845746)
167. 2-adrenergic receptor complex facilitates receptor phosphorylation and signaling. Curr. Biol. 10:409-12 (Pubitemid 30213389)
168. 2-adrenergic receptors with protein kinases and phosphatases and the role of gravin. J. Biol. Chem. 274:1588-95
169. Klein U, Ramirez MT, Kobilka BK, von Zastrow M. 1997. A novel interaction between adrenergic receptors and the a-subunit of eukaryotic initiation factor 2B. J. Biol. Chem. 272:19099-102 (Pubitemid 27337693)
170. Karoor V, Wang L, Wang HY, Malbon CC. 1998. Insulin stimulates sequestration of p-adrenergic receptors and enhanced association of p-adrenergic receptors with Grb2 via tyrosine 350.J. Biol. Chem. 273:33035-41 (Pubitemid 28557699)
171. Fan G, Shumay E, Malbon CC, Wang H. 2001. c-Src tyrosine kinase binds the p2-adrenergic receptor via phospho-Tyr-350, phosphorylates G-protein-linked receptor kinase 2, and mediates agonist-induced receptor desensitization. J. Biol. Chem. 276:13240-47
172. Cao W, Luttrell LM, Medvedev AV, Pierce KL, Daniel KW, et al. 2000. Direct binding of activated c-Src to the p3-adrenergic receptor is required for MAP kinase activation. J. Biol. Chem. 275:38131-34 (Pubitemid 32009129)
173. Zhan L, Liu B, Jose-Lafuente M, Chibalina MV, Grierson A, et al. 2008. ALG-2 interacting protein AIP1: a novel link between D1 and D3 signaling. Eur. J. Neurosci. 27:1626-33 (Pubitemid 351473578)
174. Kim OJ, Ariano MA, Lazzarini RA, Levine MS, Sibley DR. 2002. Neurofilament-M interacts with the D1 dopamine receptor to regulate cell surface expression and desensitization. J. Neurosci. 22:5920-30 (Pubitemid 35387636)
175. BermakJC, Li M, Bullock C, Weingarten P, Zhou QY. 2002. Interaction of y-COP with a transport motif in the D1 receptor C-terminus. Eur. J. Cell Biol. 81:77-85 (Pubitemid 34177174)
176. Zhang J, Vinuela A, Neely MH, Hallett PJ, Grant SG, et al. 2007. Inhibition of the dopamine D1 receptor signaling by PSD-95.J. Biol. Chem. 282:15778-89 (Pubitemid 47093305)
177. Kim OJ, Gardner BR, Williams DB,MarinecPS, Cabrera DM, etal. 2004. The role of phosphorylation in D1 dopamine receptor desensitization: evidence for a novel mechanism of arrestin association. J. Biol. Chem. 279:7999-8010 (Pubitemid 38294688)
178. Bofill-Cardona E, Kudlacek O, Yang Q, Ahorn H, FreissmuthM, Nanoff C. 2000. Binding of calmodulin to the D2 -dopamine receptor reduces receptor signaling by arresting the G protein activation switch. J. Biol. Chem. 275:32672-80
179. Binda AV, Kabbani N, Levenson R. 2005. Regulation of dense core vesicle release from PC12 cells by interaction between the D2 dopamine receptor and calcium-dependent activator protein for secretion (CAPS). Biochem. Pharmacol. 69:1451-61 (Pubitemid 40602445)
180. Bartlett SE, Enquist J, Hopf FW, Lee JH, Gladher F, et al. 2005. Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc. Natl. Acad. Sci. USA 102:11521-26 (Pubitemid 41153852)
181. Binda AV, Kabbani N, Lin R, Levenson R. 2002. D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N. Mol. Pharmacol. 62:507-13 (Pubitemid 36329368)
182. Macey TA, Gurevich VV, Neve KA. 2004. Preferential interaction between the dopamine D2 receptor and arrestin2 in neostriatal neurons. Mol. Pharmacol. 66:1635-42 (Pubitemid 39564791)
183. Kabbani N, Jeromin A, Levenson R. 2004. Dynamin-2 associates with the dopamine receptor signalplex and regulates internalization of activated D2 receptors. Cell. Signal. 16:497-503 (Pubitemid 38058632)
184. Lin R, Karpa K, Kabbani N, Goldman-Rakic P, Levenson R. 2001. Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc. Natl. Acad. Sci. USA 98:5258-63 (Pubitemid 32397116)
185. Takeuchi Y, Fukunaga K. 2003. Differential subcellular localization of two dopamine D2 receptor iso-forms in transfected NG108-15 cells. J. Neurochem. 85:1064-74 (Pubitemid 36578638)
186. Zou S, Li L, Pei L, Vukusic B, Van Tol HHM, et al. 2005. Protein-protein coupling/uncoupling enables dopamine D2 receptor regulation of AMPA receptor-mediated excitotoxicity. J. Neurosci. 25:4385-95 (Pubitemid 40628783)
187. Kim OJ, Ariano MA, Namkung Y, Marinec P, Kim E, et al. 2008. D2 dopamine receptor expression and trafficking is regulated through direct interactions with ZIP. J. Neurochem. 106:83-95 (Pubitemid 351840200)
188. Oldenhof J, Ray A, Vickery R, Van Tol HHM. 2001. SH3 ligands in the dopamine D3 receptor. Cell. Signal. 13:411-16 (Pubitemid 32510991)
189. Kim KM, Gainetdinov RR, Laporte SA, CaronMG, Barak LS. 2005. G protein-coupled receptor kinase regulates dopamine D3 receptor signaling by modulating the stability of a receptor-filamin- p-arrestin complex: a case of autoreceptor regulation. J. Biol. Chem. 280:12774-80
190. Griffon N, Jeanneteau F, Prieur F, Diaz J, Sokoloff P. 2003. CLIC6, a member of the intracellular chloride channel family, interacts with dopamine D2-like receptors. Brain Res. Mol. Brain Res. 117:47-57 (Pubitemid 37123109)
191. Oldenhof J, Vickery R, Anafi M, Oak J, Ray A, et al. 1998. SH3 binding domains in the dopamine D4 receptor. Biochemistry 37:15726-36 (Pubitemid 28524744)
192. 1A receptor at two distinct sites: putative role in receptor phosphorylation by protein kinase C. J. Biol. Chem. 279:17027-37 (Pubitemid 38560457)
193. 2A receptor: the third intracellular loop is α-helical and binds purified arrestins. J. Neurochem. 72:2206-14 (Pubitemid 29186030)
194. 2A receptor: a putative regulator of G protein coupling and receptor phosphorylation by protein kinase C. J. Biol. Chem. 280:30741-50 (Pubitemid 41291803)
195. 2A receptor. Mol. Pharmacol. 64:1239-50 (Pubitemid 37310756)
196. Bécamel C, Figge A, Poliak S, Dumuis A, Peles E, et al. 2001. Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1. J. Biol. Chem. 276:12974-82
197. Sheffler DJ, Kroeze WK, Garcia BG, Deutch AY, Hufeisen SJ, et al. 2006. p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling. Proc. Natl. Acad. Sci. USA 103:4717-22
198. 6 receptor through an interaction with Fyn. J. Biol. Chem. 282:5496-505 (Pubitemid 47093777)
199. Yun HM, Baik JH, Kang IS, Jin C, Rhim H. 2010. Physical interaction of Jab1 with human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival. J. Biol. Chem. 285:10016-29
200. 7 receptor isoforms and PLAC-24/eIF3k. Cell. Signal. 19:278-88 (Pubitemid 44969977)
201. 1 melatonin receptor. J. Biol. Chem. 283:16762-71